GAITHERSBURG, Md., May 08, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) announces receipt of the written consent of more than a majority of the voting power of its outstanding capital stock in favor of a proposed reverse split of its common stock at a specific ratio within a range from 1-for-2 to 1-for-4 to be determined by the Company’s Board of Directors.
The Company solicited the written consent of its stockholders for approval of the proposed reverse split commencing on April 28, 2017, and received the requisite written consents as of May 5, 2017. As a result, the Company has terminated the consent solicitation.
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a biomedical company offering biodynamic therapies for chronic wound care. The Company's Aurix System is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. For additional information, please visit www.nuot.com or www.aurixsystem.com.
